CM
SYRE icon

Castleark Management’s Spyre Therapeutics SYRE Stock Holding History

Castleark Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.35M Buy
+26,420
New +$1.93M 0.06% 198

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Castleark Management's SYRE Position: Q2 2026 in Review

Castleark Management opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 26,420 shares worth $2.35M. The stake represents 0.06% of the portfolio and ranks #198 among its holdings.

265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Castleark Management held 26,420 shares of Spyre Therapeutics worth $2.35M as of Q2 2026.
  • Spyre Therapeutics was a new Castleark Management position in Q2 2026.
  • Spyre Therapeutics made up 0.06% of Castleark Management's portfolio in Q2 2026, its #198 holding.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Castleark Management's 13F filing for Q2 2026, filed 14 Aug 2026.